TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

3D planning software helps cardiologists plan ahead for TAVR complications
Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues.
FDA clears AI-powered platform that personalizes care during TAVR, cardiac pacing procedures
The newly cleared CARA System from Cara Medical was designed to help clinicians before and during a variety of cardiac procedures. It provides a personalized 3D map of the patient's cardiac conduction system and then overlays that map onto live fluoroscopic images.
TAVR a safe treatment option for patients who have undergone chest radiation therapy
In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.
Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR
Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.
Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way
Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.

Matthew Summers, MD, FACC, program director for structural heart, Sentara Heart Hospital, Norfolk, Virginia, explains how his center used a new transcatheter aortic valve replacement (TAVR) 3D CT planning software to better identify patients who are at high risk of complications. The software also enables the heart team to test the best placement of various valves to create a procedure plan tailored for each patients unique anatomy.

3D planning software helps cardiologists plan ahead for TAVR complications

Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues.

simulation of the conduction pathway relative to various cardiac structures.

FDA clears AI-powered platform that personalizes care during TAVR, cardiac pacing procedures

The newly cleared CARA System from Cara Medical was designed to help clinicians before and during a variety of cardiac procedures. It provides a personalized 3D map of the patient's cardiac conduction system and then overlays that map onto live fluoroscopic images.

TAVR a safe treatment option for patients who have undergone chest radiation therapy

In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR

Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.

Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way

Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.

REVENUE MONEY INCREASE DOLLAR GRAPH FINANCE

Edwards celebrates double-digit TAVR sales growth in Q4

It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry.